Podzolkov V I, Bragina A E, Makolkin V I
Kardiologiia. 2002;42(11):32-5.
To assess efficacy of monotherapy with moxonidine in female patients with hypertension and climacteric syndrome.
Twenty-four hour blood pressure monitoring was carried out in 32 women (mean age 52.3-/+5.2 years) before and after 28 days of monotherapy with moxonidine (0.2-0.4 mg).
In 4 weeks the following significant changes were registered: lowering of systolic and diastolic blood pressures, decrease of blood pressure variability and rate of its morning rise, increase of 24-hour blood pressure index. This was accompanied by significant decrease of vascular peripheral resistance without changes of myocardial contractility. There were no significant changes of parameters of carbohydrate, lipid and purine metabolism.
Moxonidine in women with hypertension and climacteric syndrome caused blood pressure lowering at the account of decreased total peripheral resistance and restoration of physiological blood pressure rhythm.
评估莫索尼定单药治疗女性高血压患者及更年期综合征的疗效。
对32名女性（平均年龄52.3±5.2岁）在使用莫索尼定（0.2 - 0.4毫克）单药治疗28天前后进行24小时血压监测。
4周内出现以下显著变化：收缩压和舒张压降低，血压变异性及早晨血压上升速率降低，24小时血压指数升高。同时伴有血管外周阻力显著降低，而心肌收缩力无变化。碳水化合物、脂质和嘌呤代谢参数无显著变化。
莫索尼定治疗女性高血压患者及更年期综合征可通过降低总外周阻力和恢复生理性血压节律来降低血压。
